WallStSmart

Elevance Health Inc (ELV)vsRLX Technology Inc (RLX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 4477% more annual revenue ($200.42B vs $4.38B). RLX leads profitability with a 22.5% profit margin vs 2.6%. ELV trades at a lower P/E of 17.0x. RLX earns a higher WallStSmart Score of 68/100 (B-).

ELV

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.66

RLX

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 6.0Value: 5.3Quality: 9.0
Piotroski: 5/9Altman Z: 5.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ELVUndervalued (+4.5%)

Margin of Safety

+4.5%

Fair Value

$416.35

Current Price

$415.53

$0.82 discount

UndervaluedFair: $416.35Overvalued

Intrinsic value data unavailable for RLX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELV4 strengths · Avg: 8.3/10
Market CapQuality
$87.28B9/10

Large-cap with strong market position

P/E RatioValuation
17.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$4.10B8/10

Generating 4.1B in free cash flow

RLX6 strengths · Avg: 9.5/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
107.4%10/10

Revenue surging 107.4% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.6210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

EPS GrowthGrowth
27.1%8/10

Earnings expanding 27.1% YoY

Areas to Watch

ELV3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Profit MarginProfitability
2.6%3/10

2.6% margin — thin

EPS GrowthGrowth
-16.8%2/10

Earnings declined 16.8%

RLX1 concerns · Avg: 3.0/10
Return on EquityProfitability
6.2%3/10

ROE of 6.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : RLX

The strongest argument for RLX centers on Price/Book, Revenue Growth, Debt/Equity. Profitability is solid with margins at 22.5% and operating margin at 16.7%. Revenue growth of 107.4% demonstrates continued momentum.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, EPS Growth. Thin 2.6% margins leave little buffer for downturns.

Bear Case : RLX

The primary concerns for RLX are Return on Equity.

Key Dynamics to Monitor

ELV profiles as a value stock while RLX is a growth play — different risk/reward profiles.

RLX carries more volatility with a beta of 1.14 — expect wider price swings.

RLX is growing revenue faster at 107.4% — sustainability is the question.

ELV generates stronger free cash flow (4.1B), providing more financial flexibility.

Bottom Line

RLX scores higher overall (68/100 vs 56/100), backed by strong 22.5% margins and 107.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

RLX Technology Inc

CONSUMER DEFENSIVE · TOBACCO · China

RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.

Visit Website →

Want to dig deeper into these stocks?